-
1.发明公开Use of diadenosine-5',5'''-p1,p4-tetraphosphate for the manufacture of a medicament for the treatment of heart disease 失效用于治疗心脏疾病的药物的制备中使用二亚氨酸-5'，5“' - P1，P4-四磷酸
公开(公告)号：EP0437929A3
公开(公告)日：1991-09-25
申请号：EP90312713.2
申请日：1990-11-22
申请人： FUJIREBIO INC. , UNITIKA LTD.
IPC分类号： A61K31/70
摘要： Use of diadenosine 5',5'''-P¹,P⁴-tetraphosphate or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of heart disease.
-
2.发明授权Use of diadenosine-5',5'''-p1,p4-tetraphosphate for the manufacture of a medicament for the treatment of heart disease 失效二腺苷5使用”，5' ‘’ - P1，P4-四磷酸用于制备治疗心脏疾病的治疗。
公开(公告)号：EP0437929B1
公开(公告)日：1994-03-02
申请号：EP90312713.2
申请日：1990-11-22
申请人： FUJIREBIO INC. , UNITIKA LTD.
IPC分类号： A61K31/70
-
3.发明公开Use of diadenosine-5',5'''-p1,p4-tetraphosphate for the manufacture of a medicament for the treatment of heart disease 失效二腺苷5使用”，5' ‘’ - P1，P4-四磷酸用于制备治疗心脏疾病的治疗。
公开(公告)号：EP0437929A2
公开(公告)日：1991-07-24
申请号：EP90312713.2
申请日：1990-11-22
申请人： FUJIREBIO INC. , UNITIKA LTD.
IPC分类号： A61K31/70
摘要： Use of diadenosine 5',5'''-P¹,P⁴-tetraphosphate or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of heart disease.
摘要翻译： 二腺苷5”，5' ‘’的使用 - P <1>，P <4>四磷酸盐或心脏疾病的治疗的药物中的用途药学上可接受的盐。
-
公开(公告)号：EP0520336A3
公开(公告)日：1993-04-07
申请号：EP92110388.3
申请日：1992-06-19
申请人： FUJIREBIO Inc.
发明人： Hosoda, Akihiko , Nakayama, Yukihide , Shibata, Masahiro , Sekine, Yasuo , Inaba, Niro , Ikawa, Hiroshi , Yamaura, Tetsuaki , Tanabe, Naoko
IPC分类号： C07D205/04 , C07D207/16 , C07D211/36 , A61K31/395 , A61K31/40 , A61K31/445 , A61K31/16 , C07C233/31 , C07C235/06 , C07C271/22 , C07C275/16 , C07C275/18 , C07C275/28
CPC分类号： C07D401/06 , C07C215/08 , C07C215/28 , C07C217/34 , C07C217/64 , C07C229/36 , C07C233/76 , C07C271/12 , C07C271/22 , C07C271/28 , C07C271/30 , C07C323/41 , C07C333/08 , C07C2601/08 , C07C2601/14 , C07D205/04 , C07D207/16 , C07D209/14 , C07D211/60 , C07D211/62 , C07D333/18 , C07D401/12 , C07D401/14 , C07D409/06
摘要： Aldehyde derivatives with a specific calpain inhibiting activity and a platelet-aggregation inhibiting effect with formula (I) or formula (II):
wherein R 1 represents an aromatic hydrocarbon group, a heterocyclic group, or a group of -X-R 3 in which X represents O, -S(O) m - (m = 0, 1, or 2), and R 3 represents an aromatic hydrocarbon group, a heterocyclic group, or an alkyl group; Z represents R 4- Y- or R 6 0-CH(R 5 )- in which Y represents a 3- to 7-membered nitrogen-containing saturated heterocyclic group, or a single cyclic saturated hydrocarbon group, R 4 represents an alkyl group, an alkenyl group, an alkynyl group, an acyl group, a sulfonyl group, an alkoxycarbonyl group, a carbamoyl group, or a thiocarbamoyl group, R 5 represents hydrogen, an alkyl group, or an aromatic hydrocarbon group, and R 6 represents an acyl group, a carbamoyl group, a thiocarbamoyl group, or an alkyl group; and n is an integer of 1 to 5.
wherein R 7 , R 8 , R 9 , and R 10 are defined in the specification.摘要翻译： 式（I）或式（II）具有特定钙蛋白酶抑制活性和血小板聚集抑制作用的醛衍生物：其中R 1表示芳族烃基，杂环基或-XR基团 其中X表示O，-S（O）m - （m = 0,1或2），R 3表示芳族烃基，杂环基或烷基; Z表示R 4 -Y-或R 6 O-CH（R 5） - ，其中Y表示3-7元含氮饱和杂环基或单环饱和烃基， R 4表示烷基，烯基，炔基，酰基，磺酰基，烷氧基羰基，氨基甲酰基或硫代氨基甲酰基，R 5表示氢，烷基或 芳香族烃基，R 6表示酰基，氨基甲酰基，硫代氨基甲酰基或烷基; 并且n为1〜5的整数。其中R 7，R 8，R 9和R 1的定义在说明书中。
-
公开(公告)号：EP0520336A2
公开(公告)日：1992-12-30
申请号：EP92110388.3
申请日：1992-06-19
申请人： FUJIREBIO Inc.
发明人： Hosoda, Akihiko , Nakayama, Yukihide , Shibata, Masahiro , Sekine, Yasuo , Inaba, Niro , Ikawa, Hiroshi , Yamaura, Tetsuaki , Tanabe, Naoko
IPC分类号： C07D205/04 , C07D207/16 , C07D211/36 , A61K31/395 , A61K31/40 , A61K31/445 , A61K31/16 , C07C233/31 , C07C235/06 , C07C271/22 , C07C275/16 , C07C275/18 , C07C275/28
CPC分类号： C07D401/06 , C07C215/08 , C07C215/28 , C07C217/34 , C07C217/64 , C07C229/36 , C07C233/76 , C07C271/12 , C07C271/22 , C07C271/28 , C07C271/30 , C07C323/41 , C07C333/08 , C07C2601/08 , C07C2601/14 , C07D205/04 , C07D207/16 , C07D209/14 , C07D211/60 , C07D211/62 , C07D333/18 , C07D401/12 , C07D401/14 , C07D409/06
摘要： Aldehyde derivatives with a specific calpain inhibiting activity and a platelet-aggregation inhibiting effect with formula (I) or formula (II):
wherein R 1 represents an aromatic hydrocarbon group, a heterocyclic group, or a group of -X-R 3 in which X represents O, -S(O) m - (m = 0, 1, or 2), and R 3 represents an aromatic hydrocarbon group, a heterocyclic group, or an alkyl group; Z represents R 4- Y- or R 6 0-CH(R 5 )- in which Y represents a 3- to 7-membered nitrogen-containing saturated heterocyclic group, or a single cyclic saturated hydrocarbon group, R 4 represents an alkyl group, an alkenyl group, an alkynyl group, an acyl group, a sulfonyl group, an alkoxycarbonyl group, a carbamoyl group, or a thiocarbamoyl group, R 5 represents hydrogen, an alkyl group, or an aromatic hydrocarbon group, and R 6 represents an acyl group, a carbamoyl group, a thiocarbamoyl group, or an alkyl group; and n is an integer of 1 to 5.
wherein R 7 , R 8 , R 9 , and R 10 are defined in the specification.摘要翻译： 式（I）或式（II）具有特定钙蛋白酶抑制活性和血小板聚集抑制作用的醛衍生物：其中R 1表示芳族烃基，杂环基或-XR基团 其中X表示O，-S（O）m - （m = 0,1或2），R 3表示芳族烃基，杂环基或烷基; Z表示R 4 -Y-或R 6 O-CH（R 5） - ，其中Y表示3-7元含氮饱和杂环基或单环饱和烃基， R 4表示烷基，烯基，炔基，酰基，磺酰基，烷氧基羰基，氨基甲酰基或硫代氨基甲酰基，R 5表示氢，烷基或 芳香族烃基，R 6表示酰基，氨基甲酰基，硫代氨基甲酰基或烷基; 并且n为1〜5的整数。其中R 7，R 8，R 9和R 1的定义在说明书中。
-
-
-
-
搜索结果
5 条记录 (耗时 0.011 秒)
